Diplomat Pharmacy (NYSE:DPLO) updated its FY19 earnings guidance on Friday. The company provided EPS guidance of ($0.50-0.34) for the period, compared to the Thomson Reuters consensus EPS estimate of ($0.18). The company issued revenue guidance of $4.7-5.0 billion, compared to the consensus revenue estimate of $5.51 billion.Diplomat Pharmacy also updated its FY 2019 guidance to $-0.5-0.34 EPS.
Several brokerages recently issued reports on DPLO. Morgan Stanley reduced their price objective on shares of Diplomat Pharmacy from $20.00 to $18.00 and set an equal weight rating on the stock in a research note on Monday, December 3rd. Zacks Investment Research downgraded shares of Diplomat Pharmacy from a hold rating to a strong sell rating in a research note on Tuesday, November 27th. Robert W. Baird raised shares of Diplomat Pharmacy from an underperform rating to a neutral rating and upped their price objective for the company from $10.00 to $15.00 in a research note on Friday, December 7th. ValuEngine downgraded shares of Diplomat Pharmacy from a sell rating to a strong sell rating in a research note on Monday, February 4th. Finally, William Blair downgraded shares of Diplomat Pharmacy from an outperform rating to a market perform rating in a research note on Monday, January 7th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $13.78.
DPLO opened at $6.42 on Friday. The firm has a market cap of $485.54 million, a P/E ratio of 7.64 and a beta of 0.74. Diplomat Pharmacy has a twelve month low of $5.56 and a twelve month high of $28.74. The company has a quick ratio of 0.66, a current ratio of 0.95 and a debt-to-equity ratio of 0.58.
WARNING: “Diplomat Pharmacy (DPLO) Issues FY19 Earnings Guidance” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2019/03/15/diplomat-pharmacy-dplo-issues-fy19-earnings-guidance.html.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Recommended Story: How do buyers and sellers choose a strike price?
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.